{"id":"brivaracetam-brv-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Somnolence"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL607400","moleculeType":"Small molecule","molecularWeight":"212.29"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It modulates neurotransmitter release by binding to the synaptic vesicle protein SV2A, which is involved in the regulation of neurotransmitter release. This action is thought to contribute to its antiepileptic effects.","oneSentence":"Brivaracetam is a selective, high-affinity SV2A receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:55.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures"},{"name":"Primary generalized tonic-clonic seizures"}]},"trialDetails":[{"nctId":"NCT01364597","phase":"PHASE3","title":"Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2011-08-01","conditions":"Epilepsy","enrollment":257},{"nctId":"NCT03083665","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-08-22","conditions":"Partial Seizures With or Without Secondary Generalization, Epilepsy","enrollment":449},{"nctId":"NCT03250377","phase":"PHASE3","title":"A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-08-05","conditions":"Partial Seizures With or Without Secondary Generalization, Epilepsy","enrollment":207},{"nctId":"NCT04715646","phase":"PHASE3","title":"A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-03-11","conditions":"Epilepsy","enrollment":70},{"nctId":"NCT06312566","phase":"PHASE1","title":"A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2024-03-25","conditions":"Healthy Study Participants","enrollment":64},{"nctId":"NCT05315947","phase":"PHASE1","title":"A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-04-04","conditions":"Healthy Study Participants","enrollment":24},{"nctId":"NCT00368251","phase":"PHASE3","title":"Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-11","conditions":"Unverricht-Lundborg Disease","enrollment":56},{"nctId":"NCT04882540","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-05-19","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT00464269","phase":"PHASE3","title":"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-09","conditions":"Epilepsy","enrollment":400},{"nctId":"NCT01710670","phase":"PHASE1","title":"A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-09","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT00699283","phase":"PHASE3","title":"A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2008-08","conditions":"Epilepsy","enrollment":62},{"nctId":"NCT01405508","phase":"PHASE3","title":"Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-08","conditions":"Epilepsy","enrollment":105},{"nctId":"NCT01653262","phase":"PHASE3","title":"Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-07","conditions":"Epilepsy","enrollment":29},{"nctId":"NCT02088957","phase":"PHASE2","title":"Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures","status":"TERMINATED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2014-03","conditions":"Nonconvulsive Electrographic Seizures","enrollment":1},{"nctId":"NCT02602860","phase":"PHASE1","title":"A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2015-11","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT00357669","phase":"PHASE3","title":"Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2006-11","conditions":"Unverricht-Lundborg Disease","enrollment":50},{"nctId":"NCT01796899","phase":"PHASE1","title":"Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2013-01","conditions":"Healthy Volunteers","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BRV","Briviact"],"phase":"phase_3","status":"active","brandName":"brivaracetam (BRV) tablet","genericName":"brivaracetam (BRV) tablet","companyName":"UCB Biopharma SRL","companyId":"ucb-biopharma-srl","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brivaracetam is a small molecule that modulates synaptic vesicle glycoprotein 2A, a protein involved in neurotransmitter release. It is used to treat conditions such as epilepsy and has been studied in clinical trials for its potential effects on Unverricht-Lundborg Disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}